A patent foramen ovale diagnostic device based on Valsalva maneuver

By monitoring the blowing pressure and electrocardiogram change rate in real time in the patent foramen ovale diagnostic device, determining the timing of contrast agent injection and image shooting, the problems of diagnostic accuracy and operation standardization in the prior art are solved, and more efficient Diagnostic results.

CN118649310BActive Publication Date: 2024-11-26GUANGDONG GENERAL HOSPITAL
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411097019.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-26
Estimated Expiration
2044-08-12

AI Technical Summary

Technical Problem

In the existing diagnostic methods for patent foramen ova, there is a lack of unified operating standards and timing of contrast agent application, resulting in reduced diagnostic accuracy, especially in the risk of misdiagnosis in Valsalva action execution and monitoring of ECG rate.

Method used

Provided a patent-closed foramen ova based on Valsalva action, including a blowing unit, an electrocardiogram monitoring unit, a contrast agent injection unit and a control unit. By monitoring the blowing pressure and the rate of change of the ECG in real time, it determines the contrast agent injection. Timing and ultrasound imaging timing ensure that the contrast agent matches the blood flow dynamics of the heart and improves diagnostic accuracy.

Benefits of technology

It improves the accuracy of contrast agent injection timing and the accuracy of cardiac ultrasound imaging, reduces the misdiagnosis rate, provides a more accurate diagnosis basis for patent foramen ova, and reduces the difficulty of performing Valsalva actions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118649310B_ABST
    Figure CN118649310B_ABST
Patent Text Reader

Abstract

The present invention relates to a patent foramen ovale auxiliary diagnosis device based on Valsalva maneuver, comprising an air blowing unit, an electrocardiogram monitoring unit, a contrast agent injection unit and a control unit. When the air blowing pressure of a patient to be tested fed back by the air blowing unit reaches a first predetermined threshold value and is maintained for a predetermined time, the control unit starts to request the electrocardiogram change rate of the patient output by the electrocardiogram monitoring unit; when it is determined that the electrocardiogram change rate of the patient to be tested has a change inflection point related to the Valsalva maneuver, the control unit sends a prompt message of inputting contrast agent to the contrast agent injection unit; in response to the start-up message of contrast agent intravenous input of the contrast agent injection unit, the control unit sends a rapid air blowing instruction to the patient to be tested through the prompt unit, and when it is determined that the air blowing pressure of the patient to be tested measured by the air blowing unit is lower than a second predetermined threshold value, the control unit sends a recording instruction of the blood flow dynamics in the heart through the prompt unit.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medical equipment, and in particular to a patent foramen ovale auxiliary diagnosis device based on Valsalva maneuver. Background Art

[0002] The foramen ovale is a physiological passage in the atrial septum of the heart during the embryonic period. After birth, as the left atrial pressure (LAP) increases and the pulmonary artery resistance decreases, the primary and secondary atrial septums approach and fuse. In most people, the foramen ovale closes on its own within one year after birth. Those who fail to close form a potential passage in the middle of the atrial septum, namely patent foramen ovale (PFO). When the foramen ovale is not closed, blood can still pass through this small hole and flow from the right atrium to the left atrium without passing through the lungs. When coughing hard, trying to defecate, or when the air pressure changes, some people may have a blood clot that passes through the foramen ovale and enters the brain, causing a stroke.

[0003] Most PFOs are asymptomatic, but they pose a potential threat to health or life. Emboli (including thrombi, air emboli, fat emboli, etc.) originating from the systemic venous system can enter the systemic circulation through the patent foramen ovale PFO, leading to a series of clinical symptoms, including migraine, ischemic stroke, myocardial infarction, peripheral vascular embolism, decompression syndrome, etc. At present, transesophageal echocardiography (TEE) combined with right heart acoustic angiography (ASCE) and adequate provocation tests are the gold standard imaging methods for diagnosing patent foramen ovale, but there is no unified standard for the operation process and diagnostic criteria in China.

[0004] In the process of diagnosing PFO, echocardiography needs to use a provocative test to increase the right atrial pressure RAP, so that the right atrial pressure RAP is higher than the left atrial pressure LAP, in order to show the right-to-left shunt at the patent foramen ovale PFO. Whether the provocative test is adequate during the examination is highly correlated with the detection rate of patent foramen ovale PFO. Therefore, whether the provocative test is adequate should be determined before interpreting the results.

[0005] The clinical significance of the Valsalva maneuver is that it significantly reduces the amount of venous return to the heart and excites the vagus nerve by increasing the intrathoracic pressure. The Valsalva maneuver is the most commonly used provocative test. Compared with other provocative tests, the Valsalva maneuver can more significantly increase the right atrial pressure RAP and improve the sensitivity of the diagnosis of patent foramen ovale PFO. However, for critically ill patients, intubated patients, and patients undergoing sedated TEE, a full Valsalva maneuver is difficult to achieve. The following methods can be used to increase the right atrial pressure RAP, such as abdominal pressure, inferior vena cava pressurization, coughing, deep inspiration, forced exhalation, and bed tilting.

[0006] The ASCE standard for diagnosing patent foramen ovale (PFO) is the visible ASC (Agitated Saline Contrast Echocardiography) passing through the foramen ovale of the atrial septum. The appearance of ASC in the left atrium within 3 to 6 cardiac cycles after the right atrium is filled with ASC can also be used as an alternative indicator. The latter is suitable for situations where the shunt is not clearly displayed or is located in a non-current section.

[0007] Patent foramen ovale (PFO) is a congenital defect of the atrial septum that usually causes no symptoms but may be associated with certain pathological conditions, such as cryptogenic stroke and migraine. Current methods for diagnosing PFO have several limitations, especially in noninvasive screening such as transesophageal echocardiography (TEE), cardiac computed tomography (CCT), contrast transthoracic echocardiography (cTTE), and transcranial Doppler ultrasound (TCD).

[0008] Regarding transesophageal echocardiography (TEE), the literature "Patent Foramen Ovale: Pivotal Role of Transesophageal Echocardiography in the Indications for Closure, Assessment of Varying Anatomies and Post-procedure Follow-up" (Vitarelli, 2019; Pristipino et al., 2019) records that TEE is the gold standard for PFO diagnosis and is widely used due to its high accuracy. However, it is a semi-invasive examination that may cause discomfort to patients and is costly.

[0009] Regarding cardiac computed tomography (CCT), the paper "Computed Tomography for Detecting Patent Foramen Ovale: A Meta-Analysis." (Lou, J., Bao, Y., Lv, T., & Yang, Y. (2022). The heart surgery forum , 25 6, E849-E853) documented that CCT is a promising noninvasive method with high diagnostic accuracy and specificity. However, CCT has a low sensitivity and may miss small PFOs.

[0010] Regarding contrast transthoracic echocardiography (cTTE), the paper "Contrast Transthoracic Echocardiography Using 50% Glucose as a Contrast Agent for Screening of a Patent Foramen Ovale" (Li et al., 2018) proposed that cTTE is a non-invasive method that can improve diagnostic sensitivity when using 50% glucose as a contrast agent (Li et al., 2018). Although cTTE has high sensitivity and specificity, it is still not sensitive enough for small right-to-left shunts.

[0011] Regarding transcranial Doppler ultrasound (TCD), the document "Comparative analysis of the diagnostic value of several methods for the diagnosis of patent foramen ovale" (Liu et al., 2020) records that TCD is another non-invasive method suitable for preliminary screening of PFO, but it may produce false positive results, so it needs to be combined with other methods for diagnosis (Liu et al., 2020).

[0012] Regarding the combined use of the above-mentioned non-invasive screening methods, Yang et al. pointed out in "The Efficacy of Contrast Transthoracic Echocardiography and Contrast Transcranial Doppler for the Detection of Patent Foramen Ovale Related to Cryptogenic Stroke" in 2020 that the combination of cTTE and TCD methods can improve the specificity and sensitivity of diagnosis, especially when using cTTE3 + cTCD IV, the diagnostic accuracy is significantly improved.

[0013] Although existing PFO diagnostic methods have their own advantages and disadvantages, non-invasive methods have great prospects for application in routine screening, but they need to be further optimized to improve diagnostic accuracy and patient comfort.

[0014] In recent years, machine learning has been applied in electrocardiogram diagnosis. 2023 15th International Conference on Innovations in Information Technology (IIT), 61-66.), which discusses the application of convolutional neural networks (CNN) and gated recurrent unit (GRU) networks in myocardial infarction (MI) detection with high accuracy and sensitivity. Reference to "A new technique for ECG signal classification genetic algorithm Wavelet Kernel extreme learning machine" (Diker et al., 2019), which discusses the use of genetic algorithms and wavelet kernel extreme learning machines (Wavelet Kernel ELM) to classify ECG signals. The study showed that this method has excellent performance in terms of accuracy and sensitivity. Reference to "Interpretable Machine Learning Techniques in ECG-Based Heart Disease Classification: A Systematic Review" (Amrutesh et al., 2023), which discusses the use of deep transfer learning (TL) and convolutional neural networks (CNN) to analyze ECG images and improve the accuracy of cardiac abnormality detection. Machine learning is widely used in electrocardiogram diagnosis, greatly improving the accuracy and efficiency of disease detection, and providing strong support for medical diagnosis through the application of various models and algorithms.

[0015] In addition, the ultrasound imaging unit is optimized for specific ultrasound markers of PFO. For reference, "Contrast Transthoracic Echocardiography Using 50% Glucose as a Contrast Agent for Screening of a Patent Foramen Ovale." (Li et al., 2018) proposed that cTTE using 50% glucose as a contrast agent showed higher sensitivity and accuracy in detecting PFO, which was better than normal saline. "Comparison of Different Contrast Agents in Detecting Cardiac Right-to-Left Shunt in Patients with a Patent Foramen Ovale during Contrast-Transthoracic Echocardiography" (Zhao et al., 2017) compared the effects of two contrast agents in detecting right-to-left shunt of PFO in a study and found that the sensitivity of vitamin B6 and sodium bicarbonate solution was significantly higher than that of normal saline. "The Efficacy of Contrast Transthoracic Echocardiography and Contrast Transcranial Doppler for the Detection of Patent Foramen Ovale Related to Cryptogenic Stroke" (Yang et al., 2020) proposed that the detection method combining cTTE and cTCD can significantly improve the specificity and accuracy of PFO detection, especially the combination of cTTE3+cTCD IV. "Diagnostic Performance of Cardiac Computed Tomography for Detecting Patent Foramen Ovale: Evaluation Using Transesophageal Echocardiography and Catheterization as Reference Standards" (Miki et al., 2023) proposed that cardiac CT combined with contrast jet display has a higher positive predictive value in detecting PFO, and its diagnostic performance is better than CT using only contrast jet."Modified Method of Contrast Transthoracic Echocardiography for the Diagnosis of Patent Foramen Ovale" (Zhao et al., 2019) proposed that the modified Valsalva maneuver combined with contrast transthoracic echocardiography showed higher sensitivity in detecting PFO, while there was no significant difference in specificity. "Diagnosis of Patent Foramen Ovale: The Combination of Contrast Transcranial Doppler, Contrast Transthoracic Echocardiography, and Contrast Transesophageal Echocardiography" (Xiaoyue Yang et al., 2020) also proposed that a multimodal imaging method combining cTCD, cTTE, and cTEE can provide a more comprehensive PFO diagnostic strategy. It is recommended to first use cTCD for screening, then use cTTE to quantify the severity of shunt, and finally use cTEE to evaluate PFO morphology. Therefore, the optimization of ultrasound contrast agents and imaging technology plays a key role in PFO detection, and combining multiple imaging methods can significantly improve the accuracy and reliability of diagnosis.

[0016] In conventional cardiac angiography, the choice of contrast agents is crucial for obtaining high-quality imaging data. Common cardiac contrast agents include: iodine compound contrast agents (such as ioversol, iopamidol), gadolinium-based contrast agents (such as otepamol, dopamide), etc. These contrast agents have good vascular compatibility and low toxicity, and can clearly depict the heart structure and blood flow dynamics. In contrast, saline contrast is also a simple, inexpensive and relatively safe method of cardiac contrast. During the implementation process, by rapidly injecting saline containing microbubbles, these microbubbles can produce strong echoes under ultrasound, thereby enhancing the ultrasound image of the heart. This method is particularly suitable for evaluating the right side of the heart, including right ventricular function and patent foramen ovale. In clinical research and practice in Europe and the United States, saline contrast has been proven to be an effective diagnostic tool, providing a way to evaluate heart problems without the use of expensive and potentially more toxic contrast agents.

[0017] The current PFO diagnostic method and system do not provide a clear technical solution for the selection of shunt timing and the administration of contrast agents, which reduces the accuracy of PFO diagnosis. The present invention hopes to provide a new patent foramen ovale auxiliary diagnostic device that can clarify the selection of shunt timing and the administration of contrast agents for medical staff, thereby obtaining better monitoring effects and improving the accuracy of PFO diagnostic methods.

[0018] In addition, on the one hand, there are differences in understanding among those skilled in the art; on the other hand, the applicant studied a large number of documents and patents when making the present invention, but due to space limitations, not all details and contents are listed in detail. However, this does not mean that the present invention does not have the characteristics of these prior arts. On the contrary, the present invention already has all the characteristics of the prior art, and the applicant reserves the right to add relevant prior art to the background technology. Summary of the invention

[0019] Currently, transesophageal echocardiography combined with right heart acoustic contrast and adequate stimulation tests are the gold standard imaging methods for diagnosing patent foramen ovale, but there is no unified standard for the operation process and diagnostic criteria in China. Medical staff instruct patients to blow and hold their breath based on their work experience and decide the duration of each action, which makes the duration of the Valsalva maneuver performed by patients inconsistent. The timing of intravenous contrast agent injection and cardiac ultrasound imaging are all determined by medical staff based on their work experience, resulting in some cardiac ultrasound images being unable to accurately reflect the hemodynamics of the heart, thus misdiagnosing PFO.

[0020] The prior art has already presented a technical solution of setting up a Valsalva breathing detection mechanism to detect whether the patient's Valsalva breathing meets the standard and mixing the contrast agent through a contrast agent mixing injection mechanism to maintain the activity of the contrast agent. For example, the patent document with the publication number CN114272470A discloses an oval foramen screening foaming syringe, including: a Valsalva breathing detection mechanism for detecting whether the patient's Valsalva breathing meets the standard, a receiving module for receiving an external injection instruction, a contrast agent mixing injection mechanism for mixing and injecting the contrast agent, a control module for controlling the contrast agent mixing injection mechanism according to the Valsalva breathing detection mechanism and the receiving module, the control module controls the contrast agent mixing injection mechanism to mix the contrast agent, and the control module controls the contrast agent mixing injection mechanism to inject after the Valsalva breathing detection mechanism detects that the patient's Valsalva breathing meets the standard and the receiving module receives an external injection instruction. When the inhalation pressure sensor in the Valsalva breathing detection mechanism detects that the exhalation pressure reaches the preset pressure, the corresponding timing device is started to record the duration of maintaining the exhalation pressure, and when the duration reaches the preset time, it is judged that the patient's Valsalva breathing action meets the standard. However, the judgment of the patient's detection parameter indicators in this technical solution is limited to the continuous process of the state. The detection parameters that are determined to be qualified according to this threshold setting method are the results of continuous changes in the patient's physical indicators for a period of time, and cannot reflect the continuous changes in the patient's physical state (such as cardiac blood flow dynamics). If the contrast agent injection or the timing of cardiac ultrasound imaging is selected only based on the data at the end of the physiological change characteristics, the contrast agent will not be matched with the most suitable cardiac blood flow dynamics or the timing of cardiac ultrasound imaging will lag behind the actual shunt situation in the heart, which will make the detection result inaccurate. That is to say, this technical solution only determines the degree of standard execution of the patient's Valsalva breathing maneuver based on the form of the patient's Valsalva breathing maneuver, that is, it determines whether the patient completes the given action according to the current evaluation standard, but it cannot judge whether the same standard Valsalva breathing maneuver can produce the same physiological change characteristics in different patients. For example, due to individual differences among patients, the same Valsalva breathing maneuver usually produces different physiological change characteristics in different patients. The patient's physiological change characteristics (such as cardiac hemodynamics) are directly related to the accurate selection of the timing of contrast agent injection. The appropriate injection timing can ensure that the contrast agent reaches the highest concentration in a specific part of the heart, thereby ensuring that the contrast agent can achieve more accurate image feedback driven by the corresponding physiological changes, thereby obtaining clear images and helping doctors make accurate diagnoses.

[0021] The present invention hopes to accurately judge and remind the timing of cardiac shunt and the timing of contrast agent administration by providing a patent foramen ovale auxiliary diagnosis device based on the Valsalva maneuver, thereby generating accurate ultrasound images of intracardiac shunts and providing accurate diagnostic basis for patent foramen ovale.

[0022] In view of the deficiencies of the prior art, the present invention provides a patent foramen ovale auxiliary diagnosis device based on the Valsalva maneuver, comprising an air blowing unit, an electrocardiogram monitoring unit, a contrast agent injection unit and a control unit. The air blowing unit is used to measure the air blowing pressure of the patient to be tested; the electrocardiogram monitoring unit is used to measure the electrocardiogram changes of the patient to be tested; the contrast agent injection unit is used to input contrast agent into the patient to be tested; when the air blowing pressure of the patient to be tested fed back by the air blowing unit reaches a first predetermined threshold value and is maintained for a predetermined time, the control unit begins to request the electrocardiogram change rate of the patient to be tested output by the electrocardiogram monitoring unit. The present invention utilizes a control unit and a pressure sensor to collect the data and duration of the air blowing pressure, thereby providing an accurate judgment opportunity for collecting electrocardiogram changes and avoiding the patient to be tested from repeatedly performing the Valsalva maneuver.

[0023] When it is determined that the electrocardiogram change rate of the patient to be tested has a change inflection point related to the Valsalva maneuver, the control unit sends a prompt message to the contrast agent injection unit to input the contrast agent. The present invention analyzes the electrocardiogram change rate and determines the timing of the inflection point, so that the contrast agent injection unit can inject the contrast agent into the vein in time, avoids missing the injection time of the contrast agent, and can make the injection time of the contrast agent be standardized.

[0024] In response to the start-up information of the contrast agent intravenous input received from the contrast agent injection unit, the control unit issues an insufflation instruction to the patient to be tested through the prompt unit, and when it is determined that the insufflation pressure of the patient to be tested measured by the insufflation unit is lower than a second predetermined threshold value, the control unit issues a recording instruction of the hemodynamic condition in the heart through the prompt unit.

[0025] Different from the prior art, the auxiliary diagnosis device of the present invention can measure the ECG changes of the patient to be tested through the ECG monitoring unit to monitor the ECG change rate of the patient to be tested when the insufflation pressure reaches the first predetermined threshold and remains for a predetermined time, and when the ECG change rate of the patient to be tested has a change inflection point related to the Valsalva maneuver, the control unit sends a prompt information of inputting contrast agent to the contrast agent injection unit, and the control unit can send a recording instruction of the blood flow dynamics in the heart through the prompt unit according to the start information of the contrast agent intravenous input. Based on the above-mentioned distinguishing technical features, the problems to be solved by the present invention may include: how to improve the accuracy of determining the timing of contrast agent injection and how to improve the accuracy of determining the timing of cardiac ultrasound imaging, so as to generate and obtain accurate ultrasound images of intracardiac shunts, and provide accurate diagnostic basis for patent foramen ovale. The contrast agent injection unit of the present invention is connected to the control unit, and the control unit prompts the injection of contrast agent according to the monitoring results of the ECG change rate and the insufflation pressure, so as to accurately control the injection timing of the contrast agent according to the real-time data of the ECG change and the insufflation pressure, thereby improving the accuracy of diagnosis. In order to address the defects of judging the shooting timing based on work experience and the defect of being unable to visually observe the blowing conditions of the patient to be tested, the present invention can determine the shooting timing of the ultrasound image based on the changes in the blowing conditions, so as to capture the shunt conditions in the heart in time and avoid missing the best shooting opportunity due to the shooting action.

[0026] Compared with the above-mentioned prior art which only detects the patient's expiratory pressure and ignores the correlation analysis between the patient's actual Valsalva maneuver and the ECG change rate, the present invention can determine the blood flow dynamics in the heart suitable for contrast agent injection through the correlation analysis between the ECG change rate and the Valsalva maneuver in time. At this time, the blood flow dynamics in the heart suitable for contrast agent injection is characterized by the change inflection point of the ECG change rate associated with the Valsalva maneuver in time. Preferably, the ECG change rate, especially the determination of the change inflection point associated with the Valsalva maneuver in time, is performed as follows:

[0027] S01: Initial monitoring of ECG rate of change. The monitoring of ECG rate of change starts at least from the start of blowing. When the patient to be tested starts to perform the Valsalva maneuver, that is, the blowing action, the ECG monitoring unit is immediately started and starts to monitor the ECG rate of change in real time. The control unit receives the ECG signal through the ECG monitoring unit and performs preliminary analysis using the artificial intelligence semantic training model.

[0028] S02: Monitoring of sudden changes in the ECG rate of change after the insufflation pressure reaches the standard. At the time point when the insufflation pressure reaches the first predetermined threshold, the amplitude of sudden changes in the ECG rate of change begins to be monitored. When the insufflation unit detects that the insufflation pressure reaches the first predetermined threshold (e.g., 40 mmHg), the information is immediately transmitted to the control unit. The control unit then switches to a more intensive monitoring mode, focusing on the amplitude of sudden changes in the ECG rate of change.

[0029] S03: Identify the inflection point of the change in the ECG rate of change. When the mutation amplitude exceeds the variation amplitude from the time point when the blowing starts to the time point when the blowing pressure reaches the first predetermined threshold, the time point when the mutation amplitude occurs is determined as the inflection point. The control unit analyzes the ECG rate of change data from the start of the blowing to the time when the pressure reaches the standard, and searches for the mutation amplitude. Once the monitored mutation amplitude exceeds the maximum variation amplitude during the previous monitoring period, and the degree of excess reaches or exceeds a preset percentage (for example, more than 30%, preferably more than 50%, and particularly preferably more than 70%), the time point when the mutation amplitude occurs is determined as the inflection point of the ECG rate of change associated with the Valsalva maneuver.

[0030] S04: Preparation for contrast agent injection. After determining the inflection point of the ECG rate of change, the control unit immediately sends a prompt message for preparation for injection to the contrast agent injection unit. The medical staff prepares to inject contrast agent into the vein of the patient to be tested according to the instructions of the control unit.

[0031] S05: Synchronize contrast agent injection with ECG changes. After confirming that the ECG change rate meets the preset conditions, the control unit sends an injection start signal to the contrast agent injection unit. While the medical staff performs the injection action, the control unit continues to monitor the ECG change rate to ensure that the injection timing is synchronized with the inflection point of the ECG change rate.

[0032] S06: Record the dynamics of cardiac blood flow. After the injection is completed, the control unit sends an exhalation instruction to the patient to be tested through the prompt unit, and instructs the ultrasound imaging unit to start recording the dynamics of blood flow in the heart. The ultrasound imaging unit captures and records the changes in the blood flow of the heart, providing key information for diagnosis.

[0033] According to a preferred embodiment, when a blowing instruction is issued, the control unit forms a labeling prompt information through the prompt unit, and the artificial intelligence semantic training model in the control unit labels the ECG change rate of the patient to be tested sent by the ECG monitoring unit, thereby forming a training set of the ECG change rate. By collecting relevant data on ECG changes and forming a training set, it is helpful for the artificial intelligence semantic training model to learn and identify the change inflection points related to the Valsalva maneuver based on the training set.

[0034] According to a preferred embodiment, the control unit is integrated with an artificial intelligence semantic training model. After training, the artificial intelligence semantic training model analyzes and determines the change inflection point related to the Valsalva maneuver based on the electrocardiogram change rate of the patient to be tested sent by the electrocardiogram monitoring unit. The present invention analyzes the electrocardiogram change rate and timely determines the change inflection point of the heart rate by training the artificial intelligence semantic training model, thereby achieving a good effect of accurately reminding the contrast agent input time.

[0035] According to a preferred embodiment, when the control unit issues an air blowing instruction through the prompt unit, the air blowing unit monitors the air blowing pressure of the pipeline and its changes, and the control unit triggers a timing instruction to start timing the timer connected to it based on the information condition that the air blowing pressure reaches the first predetermined threshold; when the time when the air blowing pressure reaches the first predetermined threshold reaches a predetermined duration, the control unit generates instruction information for the patient to be tested to hold his breath and timing prompt information for the breath holding duration. The control unit of the present invention can monitor the changes and duration of the air blowing pressure through the timer and the pressure sensor, and can also remind the patient to be tested to cooperate to achieve the standardization of the air blowing pressure, that is, to standardize the Valsalva action of the patient to be tested, thereby reducing the situation where the patient to be tested has non-standard Valsalva actions, and improving the efficiency of the diagnosis process of patent foramen ovale.

[0036] According to a preferred embodiment, in response to the end information of the contrast medium intravenous input of the contrast medium injection unit, the control unit issues an exhalation instruction to the patient to be tested through the prompt unit, and determines whether the insufflation pressure of the patient to be tested measured by the insufflation unit is lower than the second predetermined threshold value. Different from the prior art, the control unit of the present invention can issue corresponding breathing instructions to the patient to be tested through the prompt unit according to the contrast medium intravenous input process. Based on the above-mentioned distinguishing technical features, the problems to be solved by the present invention may include: how to reduce the difficulty of the patient to be tested to perform the Valsalva maneuver without affecting the accuracy of the test results. Specifically, in the absence of clear instructions, the patient to be tested is likely to maintain a breath-holding state or inhale in advance due to uncertainty as to whether he can breathe, which easily leads to dizziness, hypoxia and non-standard Valsalva maneuvers in the patient after performing the Valsalva maneuver. The present invention issues clear instructions by monitoring the insufflation pressure, making it easier for the patient to cooperate and reducing the difficulty of performing the standard Valsalva maneuver.

[0037] According to a preferred embodiment, the blowing unit includes a pressure sensor, a pressure communication port, a blowing assembly and a pipeline. The pressure sensor is arranged in the pipeline connected to the blowing assembly to collect the blowing pressure; the pressure sensor sends the data information of the blowing pressure to the control unit through the pressure communication port. The present invention monitors the blowing pressure and its changes through the control unit and the pressure sensor, which is more conducive to timely issuing the correct instructions for the timing of the implementation of the actions such as blowing, inhaling, and holding the breath, realizing the standardization of the Valsalva action, and improving the effectiveness of the shooting of the ultrasonic image of the heart.

[0038] According to a preferred embodiment, the ECG changes measured by the ECG monitoring unit include changes in heart rate, changes in P waves, and changes in QRS complex waves; the ECG monitoring unit compares the ECGs of the patient to be tested before and after the Valsalva maneuver to measure the ECG changes. By comparing the ECGs before and after the Valsalva maneuver, the present invention can more timely determine the changes in heart rate and the turning point of the heart rate.

[0039] According to a preferred embodiment, the device further includes a display unit. Based on the change of the insufflation pressure, the control unit controls the display unit to display the change of the insufflation pressure in different pressure ranges in the form of a change in a mark, so as to remind the patient to be tested or the medical staff of the current insufflation status. This is conducive to the patient to be tested and the medical staff to know the current insufflation status according to the change in the mark, so as to actively cooperate to complete the diagnosis process.

[0040] According to a preferred embodiment, the control unit synchronously displays the insufflation pressure and its changes, timing information and ECG changes through the display unit. The present invention integrates the three types of information into the same display unit, so that medical staff can know the changes of various types of information at the same time, and perform various operations in time according to the received prompt instructions, thereby realizing the standardization of the diagnosis operation of patent foramen ovale.

[0041] According to a preferred embodiment, when the heart rate of the patient to be tested slows down and reaches a preset heart rate threshold, the control unit sends a prompt message to the contrast agent injection unit to input contrast agent. When the preset heart rate threshold is reached, the inflection point of the heart rate change is reached. The accurate judgment and reminder of this timing can prevent medical staff from missing the best time for ultrasound imaging, so that the blood flow changes of the heart at the best time can be obtained, avoiding missing the best shooting time and providing the most accurate diagnosis basis.

[0042] According to a preferred embodiment, during the preparation of the contrast agent, the contrast agent is uniformly mixed with air by repeatedly pulling out the syringe to form a uniform mixture of air and contrast agent. The advantages of this are: it can improve the quality of the image captured, making the contours of the internal structure clearer; it reduces the demand for contrast agent, and reduces the side effects and allergic reactions that patients may experience; the contrast agent mixed with air is more evenly distributed and may also reduce the viscosity, so that the mixture is easier to inject and transport. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 It is a schematic diagram of the hardware connection relationship of the auxiliary diagnosis device for patent foramen ovale provided by the present invention;

[0044] Figure 2 It is a schematic diagram of the logical connection relationship of the auxiliary diagnosis device for patent foramen ovale provided by the present invention;

[0045] Figure 3 is a schematic diagram of a screen of a display unit provided by the present invention;

[0046] Figure 4 is a schematic diagram of the steps of the contrast agent administration method provided by the present invention;

[0047] Figure 5 It is a logical diagram of the diagnostic method of patent foramen ovale based on Valsalva maneuver;

[0048] Figure 6 is a schematic diagram of one of the PFO diagnostic images of patient A;

[0049] Figure 7 is a schematic diagram of another PFO diagnostic image of patient A;

[0050] Figure 8 is a schematic diagram of one of the PFO diagnostic images of patient B.

[0051] Reference numerals list

[0052] 100: blowing unit; 110: pressure sensor; 120: pressure communication port; 130: blowing assembly; 140: pipeline; 200: ECG monitoring unit; 210: ECG communication port; 220: electrode; 230: sensing module; 300: contrast agent injection unit; 310: contrast agent; 320: syringe; 330: actuator; 340: injection cavity; 350: injection communication port; 400: ultrasound imaging unit; 410: ultrasound probe; 420: image communication port; 500: control unit; 510: prompt unit; 520: control communication port; 530: processor; 540: artificial intelligence semantic training model; 550: memory; 560: timer; 600: patient to be tested; 700: display unit. DETAILED DESCRIPTION

[0053] The following is a detailed description with reference to the accompanying drawings.

[0054] The Valsalva test is a clinical physiological test in which the patient performs a forceful exhalation-closure maneuver, that is, taking a deep breath, closing the glottis, and then exhaling forcefully, while exhaling against the tightly closed epiglottis. This increases the intrathoracic pressure and affects the blood circulation and the state of the autonomic nervous system, thereby achieving the purpose of diagnosis and treatment.

[0055] In the present invention, a mixture of physiological saline and air is selected as the contrast medium 310 .

[0056] A saline-air mixture can be used as a contrast agent for echocardiography 310, particularly in the assessment of right ventricular function and for detection of a patent foramen ovale (PFO). This contrast agent 310, commonly referred to as "saline contrast" or "contrast echocardiography," is a rapid injection of saline containing microbubbles to enhance ultrasound images.

[0057] In the present invention, Figure 4 As shown, the method of administering "saline contrast" or "ultrasound contrast" includes the following steps:

[0058] S11: Preparation step: Take a certain amount of physiological saline, for example, 9 ml of physiological saline. The specific volume of the physiological saline is obtained as needed and is not limited here.

[0059] S12: Mixing step: Mix 9 ml of saline with 1 ml of air to form a solution containing microbubbles. This can be achieved by quickly and repeatedly pushing and pulling two 10 ml spiral syringes connected by a three-way connection 20 to 30 times to allow the saline and air to be fully mixed.

[0060] Preferably, during the preparation of the contrast agent 310 , the contrast agent 310 is uniformly mixed with air by repeatedly drawing the syringe 320 , so as to form a uniform mixture of air and contrast agent 310 .

[0061] S13: Intravenous injection procedure: The microbubble mixture is rapidly injected into a vein, usually into the elbow.

[0062] S14: Monitoring step: Immediately after injection, ultrasound observation is performed to assess the contrast effect and cardiac structure. Example 1

[0063] Currently, transesophageal echocardiography (TEE) combined with right heart acoustic contrast (ASCE) and adequate stimulation test is the gold standard imaging method for diagnosing patent foramen ovale, but there is no unified standard for the operation process and diagnostic criteria in China. Based on work experience, medical staff instructed the patient 600 to blow and hold their breath and decided the duration of each action, which made the duration of the Valsalva maneuver of the patient 600 to be tested inconsistent. The timing of injecting contrast agent 310 into the vein and taking cardiac ultrasound images were all determined by medical staff based on work experience, resulting in some cardiac ultrasound images being unable to accurately reflect the hemodynamics of the heart, thus misdiagnosing PFO.

[0064] The present invention hopes to accurately judge and remind the timing of cardiac shunt and the timing of contrast agent 310 administration by providing a patent foramen ovale auxiliary diagnosis device based on the Valsalva maneuver, thereby generating accurate ultrasound images of intracardiac shunts and providing accurate diagnostic basis for patent foramen ovale.

[0065] In view of the shortcomings of the prior art, the present invention provides a patent foramen ovale auxiliary diagnosis device based on the Valsalva maneuver, such as Figure 1 As shown, it includes an air blowing unit 100, an ECG monitoring unit 200 and a contrast agent injection unit 300. Figure 2 As shown, the blowing unit 100 , the ECG monitoring unit 200 and the contrast agent injection unit 300 are respectively connected to the control unit 500 for communication.

[0066] like Figure 1 and Figure 2 As shown, the blowing unit 100 is used to measure the blowing pressure of the patient 600 to be tested. Preferably, the blowing unit 100 includes a pressure sensor 110, a pressure communication port 120, a blowing assembly 130 and a pipe 140, and the pressure sensor 110 is arranged in the pipe 140 connected to the blowing assembly 130 to collect the blowing pressure. The pressure sensor 110 sends the data information of the blowing pressure to the control unit 500 through the pressure communication port 120. The present invention monitors the blowing pressure and its changes through the control unit 500 and the pressure sensor 110, which is more conducive to timely issuing the correct instructions for the timing of the implementation of the actions such as blowing, inhalation, and breath holding, so as to achieve the standardization of the Valsalva action and improve the effectiveness of the shooting of the ultrasonic image of the heart.

[0067] like Figure 1 and Figure 2 As shown, the ECG monitoring unit 200 is used to measure the ECG changes of the patient 600 to be tested. The ECG monitoring unit 200 includes an ECG communication port 210, a sensing module 230, a wire and an electrode 220. The sensing module 230 is located in the monitoring and display component box and is connected to the electrode 220 through a wire. The sensing module 230 is mainly responsible for sensing the ECG signal of the patient 600 to be tested. It is usually composed of one or more electrodes 220 through a wire, and these electrodes 220 will contact the body of the patient 600 to detect changes in the ECG signal. The electrode 220 can be attached to the radial artery of the patient 600 to be tested by adhesive tape. The electromyographic signal collected by the electrode 220 constructs an ECG, and the ECG waveform is displayed on the display unit 700. The sensing module 230 is connected to the control unit 500 for communication through the ECG communication port 210.

[0068] For example, when the heart contracts, the generated electromyographic signals are transmitted to the sensing module 230 through the electrodes 220 and the wires. The sensing module 230 receives and amplifies these electrical signals and converts them into digital signals. The digital signals are then transmitted to the ECG communication port 210 and transmitted to the display unit 700 through the connected control unit 500 for monitoring and observation by medical staff.

[0069] like Figure 1 and Figure 2 As shown, the contrast agent injection unit 300 is used to input contrast agent 310 to the patient 600 to be tested. The contrast agent injection unit 300 includes contrast agent 310 and a syringe 320. Preferably, the syringe 320 is two 10 ml spiral syringes 320 arranged in a three-way connection so that medical staff can manually inject contrast agent 310. In the case where the syringe 320 can be controlled by the control unit 500, the syringe 320 also includes an actuator 330 that can perform push and pull. The contrast agent 310 is filled in the injection cavity 340 of the syringe 320. The actuator 330 is connected to the control unit 500 through the injection communication port 350. The actuator 330 is, for example, a displacement sensor arranged on the push rod of the syringe 320. The displacement sensor sends the displacement data to the control unit 500 through the injection communication port 350, so that the control unit 500 can determine the injection action and injection stop time of the syringe 320 according to the displacement data.

[0070] like Figure 1 and Figure 2As shown, the ultrasound imaging unit 400 is used to image the blood flow dynamics in the heart of the patient 600 to monitor the right-to-left intracardiac shunt at the atrial level. The ultrasound imaging unit 400 includes an ultrasound image shooting body, an ultrasound probe 410, and an image communication port 420. The ultrasound image shooting body feeds back information on whether the shooting action is completed to the control unit 500 through the image communication port 420.

[0071] like Figure 2 As shown, when the insufflation pressure of the patient 600 to be tested fed back by the insufflation unit 100 reaches the first predetermined threshold value and is maintained for a predetermined time, the control unit 500 starts to request the electrocardiogram change rate of the patient 600 to be tested output by the electrocardiogram monitoring unit 200. The present invention uses the control unit 500 and the pressure sensor 110 to collect the data and duration of the insufflation pressure, thereby providing an accurate judgment opportunity for collecting electrocardiogram changes and avoiding the patient 600 to be tested from repeatedly performing the Valsalva maneuver.

[0072] For example, in order to ensure the accuracy and effectiveness of the examination process, the patient 600 to be tested needs to receive detailed instructions before undergoing cardiac angiography to correctly perform the Valsalva maneuver. Specifically, the patient 600 to be tested needs to perform this specific operation under the guidance of a medical professional: first take a deep breath, then try to exhale forcefully, but at the same time keep the airway closed, even if the gas cannot actually be discharged from the body. This forceful exhalation action, similar to the effort to defecate or hold your breath, gives the gas a moving pressure and flow rate, so that the gas generates pressure in the pipe 140. When the gas pressure in the pipe 140 reaches a pressure of 40 mmHg, the maintenance time of the gas above 40 mmHg is calculated. Generally, the patient 600 to be tested needs to maintain the pressure in the pipe 140 above 40 mmHg for 4 to 5 seconds. When the pressure in the pipe 140 is maintained above 40 mmHg for 4 to 5 seconds, the control unit 500 begins to request the electrocardiogram change rate of the patient 600 to be tested output by the electrocardiogram monitoring unit 200. Through this action, the cardiovascular system of the patient 600 to be tested will have a series of physiological reactions, and these reactions are very important for the diagnosis of patent foramen ovale (PFO).

[0073] Preferably, the control unit 500 is a processor, a dedicated integrated chip or a server capable of executing the information processing steps of the present invention. The control unit 500 includes a prompt unit 510, a control communication port 520, a processor 530, a memory 550 and a timer 560. The prompt unit 510, the control communication port 520, the memory 550 and the timer 560 are respectively connected to the processor 530 in a wired or wireless manner and realize the transmission of information. The control communication port 520 is used for communication and belongs to a communication port. The prompt unit 510 includes a sound reminder component and a light component. The prompt unit 510 can receive the instruction information issued by the processor 530 and issue a sound or light prompt information corresponding to the instruction information. The memory 550 is used to store the data information of the processor 530. The timer 560 can be a timing program in the processor 530, or it can be a specific clock. The processor 530 is used to specifically perform tasks such as data analysis and instruction generation in the control unit 500, and is a core component of the control unit 500.

[0074] In advanced medical imaging technology, ensuring accurate injection of contrast agent 310 is a crucial link, which not only affects the imaging quality, but also directly relates to the safety and comfort of the patient 600 to be tested. In this context, the design of the control unit 500 fully considers the real-time monitoring and analysis of electrocardiogram (ECG) data, and how to optimize the timing of contrast agent 310 injection based on these data. Valsalva maneuver, as a simple physiological exercise, can cause significant changes in the ECG rate of change, which provides a unique window for monitoring and evaluating heart function. When the patient 600 to be tested performs the Valsalva maneuver, the heart rate usually goes through a process of rapid rise and then slow decline, during which one or more inflection points of slowing heart rate may occur. These inflection points reflect the heart's ability to respond to physiological pressure and are ideal indicators for accurate contrast agent 310 injection.

[0075] When it is determined that the ECG change rate of the patient 600 has a change inflection point related to the Valsalva maneuver, the control unit 500 sends a prompt message to the contrast agent injection unit 300 to input the contrast agent 310. Preferably, the change inflection point refers to an inflection point where the heart rate slows down.

[0076] For example, after receiving the electrocardiogram data of the patient 600 to be tested, the control unit 500 is responsible for analyzing the electrocardiogram data of the patient 600 to be tested in real time. When the patient 600 to be tested performs the Valsalva maneuver, the control unit 500 analyzes the electrocardiogram change rate in real time and identifies the inflection point of the heart rate slowing down through an algorithm. This judgment is based on the in-depth analysis of the electrocardiogram data, including key parameters such as the heart rate change trend, the heart rate change amplitude, and the heart rate change rate. Once the inflection point of the slowing down of the heart rate is detected, the control unit 500 will immediately send a prompt message to the contrast agent injection unit 300. This prompt message contains all the necessary instructions and parameters to ensure that the contrast agent 310 can be accurately injected at the best time. The contrast agent injection unit 300 injects immediately after receiving the push prompt and cannot be left still or stopped. The automation and intelligence of this process significantly improves the efficiency and safety of the use of the contrast agent 310, and also reduces unnecessary repeated inspections caused by poor injection timing. The present invention can standardize the injection timing of the contrast agent 310.

[0077] The ECG changes measured by the ECG monitoring unit 200 include changes in heart rate, changes in P waves, and changes in QRS complex waves. The ECG monitoring unit 200 measures the ECG changes by comparing the ECGs of the patient 600 before and after the Valsalva maneuver. The present invention captures the cardiac physiological response caused by the Valsalva maneuver by comparing the ECGs before and after the Valsalva maneuver, providing important information for subsequent diagnosis and treatment.

[0078] According to a preferred embodiment, the control unit 500 is integrated with an artificial intelligence semantic training model 540. After training, the artificial intelligence semantic training model 540 analyzes the ECG change rate of the patient 600 to be tested sent by the ECG monitoring unit 200 and determines the change inflection point related to the Valsalva maneuver.

[0079] Preferably, the artificial intelligence semantic training model 540 can be obtained by training a deep neural network (DNN). A deep neural network is a network structure composed of multiple layers of artificial neurons, which simulate the working mode of neurons in the human brain and can learn and recognize complex data patterns.

[0080] A key step in the training process of the artificial intelligence semantic training model 540 is to use a large amount of electrocardiogram (ECG) data as training samples. These samples contain various patterns of normal and abnormal ECGs, especially data on ECG change rates and change inflection points related to the Valsalva maneuver. Through these data, the artificial intelligence semantic training model 540 learns how to identify the changing trend of heart rate, especially the change inflection points, which is crucial for subsequent medical decisions.

[0081] The training process of the artificial intelligence semantic training model 540 adopts a supervised learning method, in which each training sample has a corresponding label, that is, the correct interpretation of the electrocardiogram data represented by the sample (for example, whether a change inflection point associated with the Valsalva maneuver has occurred). The artificial intelligence semantic training model 540 gradually improves its accuracy and reliability in electrocardiogram data analysis by continuously adjusting the weights and biases in the network to minimize the difference between the predicted results and the true labels.

[0082] In addition, the artificial intelligence semantic training model 540 may also use specific technologies to optimize the training process, such as a convolutional neural network (CNN) to extract local features in the electrocardiogram data, or a recurrent neural network (RNN) to process the time dependency in the sequence data. The application of these technologies further enhances the ability of the artificial intelligence semantic training model 540 to process complex electrocardiogram data, enabling it to more accurately identify and analyze the electrocardiogram change rate and change inflection point associated with the Valsalva maneuver.

[0083] Although the artificial intelligence semantic training model 540 for identifying the change inflection point related to the Valsalva maneuver can be formed through the intelligent network model such as the neural network model and the enhanced deep learning model, the disadvantage of this formation is that the change inflection point related to the Valsalva maneuver automatically learned and identified by the intelligent network model may be misjudged. Especially when the ECG change rate of the patient to be tested is different from that of ordinary patients, for the special ECG change rate, the artificial intelligence semantic training model 540 is easy to automatically generate inaccurate recognition results, misleading doctors to misdiagnose. Therefore, based on this defect, the artificial intelligence semantic training model 540 retrieves the training set data based on the training set and identifies the change inflection point of the ECG change rate related to the Valsalva maneuver, and the result obtained will be more accurate. When the patient's physiological characteristics are special, or the artificial intelligence semantic training model 540 cannot find approximate data from the training set, the artificial intelligence semantic training model 540 can send a prompt message of manual intervention through the prompt unit 510, so that medical staff can judge the change inflection point related to the Valsalva maneuver. This can fully avoid the judgment results automatically generated by the artificial intelligence semantic training model 540, avoid the occurrence of erroneous results, and avoid misleading medical staff.

[0084] Specifically, when a blowing command is issued, the control unit 500 forms a labeling prompt information through the prompt unit 510, and the artificial intelligence semantic training model 540 in the control unit 500 labels the ECG change rate of the patient 600 to be tested sent by the ECG monitoring unit 200, thereby forming a training set of ECG change rate. When the patient performs the Valsalva maneuver, the ECG data will show a specific change pattern, especially the change in heart rate. During the Valsalva maneuver, the heart rate usually increases first and then drops rapidly after the maneuver ends. These changes can be observed through the RR interval of the ECG signal (i.e., the time interval between two consecutive heartbeats). Inflection point data usually refers to the start and end points of the heart rate change.

[0085] Table 1: Example data of the training set table.

[0086]

[0087] In Table 1, the "@" symbol is used to connect the time point and the corresponding heart rate value, indicating that these data were measured at the same time point. This representation method helps to clearly display the heart rate data at different time points, making the data reading more intuitive. For example, "70bpm @ 09:05" means that at the time point of 09:05, the patient's heart rate was 70 beats / minute. This format is commonly used in medical records and data analysis to ensure that the relationship between time and related measurements is clear at a glance.

[0088] In Table 1, the initial heart rate and time indicate the heart rate and time recorded before the Valsalva maneuver.

[0089] The heart rate increase inflection point indicates the inflection point and time of the heart rate increase during the Valsalva maneuver.

[0090] The heart rate reduction inflection point indicates the inflection point and time of the heart rate decrease after the Valsalva maneuver is completed.

[0091] Final heart rate and time indicate the heart rate and time recorded after the Valsalva maneuver is completed.

[0092] Heart rate variability (ΔHR / ΔT) indicates the rate of change of heart rate during the Valsalva maneuver, expressed as the change in beats per minute.

[0093] The annotation information represents the description of the characteristics of heart rate changes and is used to assist artificial intelligence models in understanding the data.

[0094] The present invention trains the artificial intelligence semantic training model 540 to retrieve the training set to analyze the ECG change rate and timely determine the turning point of the heart rate change, thereby achieving a good effect of accurately reminding the contrast agent input time.

[0095] The present invention utilizes artificial intelligence algorithms to further optimize the analysis of ECG change rate. By learning from a large amount of sample data, the artificial intelligence semantic training model 540 can more accurately identify the ECG change characteristics associated with patent foramen ovale, thereby improving the accuracy and efficiency of diagnosis.

[0096] In response to the start-up information of the contrast agent intravenous input received from the contrast agent injection unit 300, the control unit 500 issues an insufflation instruction to the patient to be tested 600 through the prompt unit 510, and when it is determined that the insufflation pressure of the patient to be tested 600 measured by the insufflation unit 100 is lower than a second predetermined threshold value, the control unit 500 issues a recording instruction of the hemodynamic condition in the heart through the prompt unit 510, so that the ultrasonic imaging unit 400 starts to take images of the hemodynamic condition in the heart.

[0097] In order to address the defects of judging the shooting timing based on work experience and the defect of not being able to visually observe the blowing conditions of the patient 600 to be tested, the present invention can determine the shooting timing of the ultrasound image based on the changes in the blowing conditions, so as to timely capture the shunt conditions in the heart and avoid missing the best shooting time due to the shooting action.

[0098] According to a preferred embodiment, when the control unit 500 issues an insufflation instruction through the prompt unit 510, the insufflation unit 100 monitors the insufflation pressure and its changes of the pipeline 140, and the control unit 500 triggers a timing instruction to start timing of the timer 560 connected thereto based on the information condition that the insufflation pressure reaches the first predetermined threshold. When the time when the insufflation pressure reaches the first predetermined threshold reaches a predetermined duration, the control unit 500 generates instruction information for the patient to be tested 600 to hold his breath and timing prompt information for the breath holding duration. The control unit 500 of the present invention can monitor the change and duration of the insufflation pressure through the timer 560 and the pressure sensor 110, and can also remind the patient to be tested 600 to cooperate to achieve the standardization of the insufflation pressure, that is, to standardize the Valsalva action of the patient to be tested 600, thereby reducing the situation where the patient to be tested 600 has non-standard Valsalva actions, and improving the efficiency of the diagnosis process of patent foramen ovale.

[0099] According to a preferred embodiment, in response to the end information of the contrast medium intravenous input of the contrast medium injection unit 300, the control unit 500 issues an exhalation instruction to the patient 600 to be tested through the prompt unit 510, and determines whether the insufflation pressure of the patient 600 to be tested measured by the insufflation unit 100 is lower than the second predetermined threshold value. In the absence of clear instructions, the patient 600 to be tested is likely to maintain a breath-holding state or inhale in advance due to uncertainty as to whether he can breathe, which may easily lead to dizziness, hypoxia, and non-standard Valsalva maneuvers in the patient 600 to be tested after performing the Valsalva maneuver. The present invention issues clear instructions by monitoring the insufflation pressure, making it easier for the patient 600 to cooperate and reducing the difficulty of performing the standard Valsalva maneuver.

[0100] For example, during the Valsalva maneuver of the patient 600 to be tested, the patient 600 to be tested blows air through the hose, and the blowing pressure must reach 40 mmHg (the first predetermined threshold value). After reaching the threshold, the patient must hold his breath for 10 seconds (preset duration). The effective Valsalva maneuver will show a process of decreasing → increasing → maintaining → decreasing in the heart rate. The heart rate changes of the patient 600 to be tested are compared by recording an electrocardiogram. The medical staff pushes the contrast agent 310 during the heart rate maintenance period of the patient 600 to be tested (holding breath for about 7 seconds). After pushing the contrast agent 310, the patient 600 to be tested exhales (resumes breathing). After exhaling, the doctor observes the intracardiac shunt situation of the patient 600 to be tested through the ultrasonic imaging unit 400, and diagnoses whether there is a patent foramen ovale and the level of the shunt according to the shunt situation.

[0101] The present invention improves the diagnostic accuracy and operation safety of patent foramen ovale by elaborating on the selection and application of cardiac contrast agent 310 and the method of accurately setting the insufflation pressure and the ECG change rate, and has important application value for clinical diagnosis.

[0102] According to a preferred embodiment, the device further includes a display unit 700. Based on the change of the insufflation pressure, the control unit 500 controls the display unit 700 to display the change of the insufflation pressure in different pressure ranges in the form of a change in a mark, so as to remind the patient 600 to be tested or the medical staff of the current insufflation status. This is conducive to the patient 600 to be tested and the medical staff to know the current insufflation status according to the change in the mark, so as to actively cooperate to complete the diagnosis process.

[0103] According to a preferred embodiment, the control unit 500 synchronously displays the insufflation pressure and its changes, timing information and ECG changes through the display unit 700. The present invention integrates the three types of information into the same display unit 700, so that medical staff can know the changes of various types of information at the same time, and perform various operations in time according to the received prompt instructions, thereby realizing the standardization of the diagnosis operation of patent foramen ovale.

[0104] For example, Figure 3 As shown, the display information of the display unit 700 is divided into three rows, the top row shows red light, yellow light, and green light, the middle row shows pressure value and timing time, and the bottom row shows electrocardiogram.

[0105] The pressure sensor 110 monitors the insufflation pressure of the patient 600 to be tested when insufflating, and displays the pressure value on the display unit 700. When >40 mmHg, the green light is on, when 36-40 mmHg, the yellow light is on, and when below 35 mmHg, the red light is on. The light is off in the non-pressure state. When the pressure is >40 mmHg, the timer 560 is triggered to count for 10 seconds, and the value is displayed on the display unit 700.

[0106] According to a preferred embodiment, when the heart rate of the patient 600 to be tested slows down and reaches a preset heart rate threshold, the control unit 500 sends a prompt message to the contrast agent injection unit 300 to input contrast agent 310. When the preset heart rate threshold is reached, the inflection point of the heart rate change is reached. The accurate judgment and reminder of this timing can prevent medical staff from missing the best time for ultrasound imaging, so that the blood flow changes of the heart at the best time can be obtained, avoiding missing the best shooting time, and providing the most accurate diagnosis basis.

[0107] like Figure 6 and Figure 7 Two ultrasound images of the heart of patient A are shown. Contrast agent 310 has been injected into patient A. Patient A is a 10-year-old child. During the Valsalva maneuver as instructed, "resting level 3, Valsalva level 3", breath holding time is 13 seconds, and heart rate changes. The contrast agent 310 in the ultrasound image of the heart is clearly visible and easy to identify. Figure 6 and Figure 7 In the cardiac ultrasound image of , there is no flow of contrast agent 310 from right to left. Patient A does not have a patent foramen ovale.

[0108] Figure 8 A cardiac ultrasound image of patient B is shown. Contrast agent 310 has been injected into patient B. Patient B is 18 years old. During the Valsalva maneuver, he followed the instructions, "resting 1 level, Valsalva 1 level", held his breath for 15 seconds, and his heart rate changed. The contrast agent 310 in the cardiac ultrasound image is clear and easy to identify. Figure 8 In the cardiac ultrasound image of FIG. 3 , there is a flow trace of contrast agent 310 flowing from right to left. Patient B has an open foramen ovale.

[0109] According to the experimental results of auxiliary diagnosis of patent foramen ovale based on Valsalva maneuver, the present invention processes the uniform foaming of contrast agent 310, so that contrast agent 310 in the ultrasound image can be clearly displayed, thereby providing clear diagnostic reference information. The medical staff of the present invention can take clear cardiac ultrasound images in time under appropriate instructions and reminders, and there is no need to ask the patient to repeat the Valsalva maneuver before a qualified image is taken, which also reduces the difficulty of patient cooperation. Example 2

[0110] This embodiment is a further improvement on Embodiment 1, and the repeated contents will not be repeated here.

[0111] This embodiment also provides a method for assisting diagnosis of patent foramen ovale based on the Valsalva maneuver. Figure 5 As shown, the following steps are included.

[0112] S000 : During the preparation of the contrast agent 310 , the contrast agent 310 is uniformly mixed with air by repeatedly pulling out the syringe 320 , so as to form a uniform mixture of air and contrast agent 310 .

[0113] S100: When the insufflation pressure of the patient 600 fed back by the insufflation unit 100 reaches the first predetermined threshold and is maintained for a predetermined time, the control unit 500 starts to request the electrocardiogram change rate of the patient 600 output by the electrocardiogram monitoring unit 200. The present invention uses the control unit 500 and the pressure sensor 110 to collect the data and duration of the insufflation pressure, thereby providing an accurate judgment opportunity for collecting electrocardiogram changes and avoiding the patient 600 from repeatedly performing the Valsalva maneuver.

[0114] S110: When the control unit 500 issues an air blowing instruction through the prompt unit 510, the air blowing unit 100 monitors the air blowing pressure and its changes in the pipeline 140, and the control unit 500 triggers a timing instruction to start timing the timer 560 connected thereto based on the information condition that the air blowing pressure reaches a first predetermined threshold value; when the time when the air blowing pressure reaches the first predetermined threshold value reaches a predetermined duration, the control unit 500 generates instruction information for the patient to be tested 600 to hold his breath and timing prompt information for the duration of holding his breath.

[0115] S200: When it is determined that the ECG change rate of the patient 600 to be tested has a change inflection point related to the Valsalva maneuver, the control unit 500 sends a prompt message to the contrast agent injection unit 300 to input the contrast agent 310. The present invention analyzes the ECG change rate and determines the timing of the inflection point, so that the contrast agent injection unit 300 can timely inject the contrast agent 310 into the vein, avoids missing the injection timing of the contrast agent 310, and can make the injection timing of the contrast agent 310 standardized.

[0116] S210: When the heart rate of the patient 600 to be tested slows down and reaches the preset heart rate threshold, the control unit 500 sends a prompt message to the contrast agent injection unit 300 to input the contrast agent 310. When the preset heart rate threshold is reached, the turning point of the heart rate change is reached. The accurate judgment and reminder of this timing can prevent medical staff from missing the best time for ultrasound imaging, so as to obtain the blood flow changes of the heart at the best time, avoid missing the best shooting time, and provide the most accurate diagnosis basis. The preset heart rate threshold is, for example, 5-10 beats / minute.

[0117] S220: A dose of 1 ml of air + 9 ml of normal saline (contrast agent 310) is injected into the vein.

[0118] S300: In response to the contrast agent intravenous input start information received from the contrast agent injection unit 300, the control unit 500 issues an air blowing instruction to the patient to be tested 600 through the prompt unit 510, and when it is determined that the air blowing pressure of the patient to be tested 600 measured by the air blowing unit 100 is lower than the second predetermined threshold, the control unit 500 issues a recording instruction of the blood flow dynamics in the heart through the prompt unit 510. In view of the defects of judging the shooting time based on work experience and the defect that the air blowing situation of the patient to be tested 600 cannot be observed intuitively, the present invention can determine the shooting time of the ultrasound image based on the change of the air blowing situation, so as to capture the shunt situation in the heart in time and avoid missing the best shooting time.

[0119] S310: In response to the end information of the contrast agent intravenous input of the contrast agent injection unit 300, the control unit 500 issues an exhalation instruction to the patient 600 to be tested through the prompt unit 510, and determines whether the insufflation pressure of the patient 600 to be tested measured by the insufflation unit 100 is lower than a second predetermined threshold.

[0120] S320: The control unit 500 sends a reminder instruction for imaging the blood flow dynamics in the heart to the ultrasonic imaging unit 400.

[0121] It should be noted that the above-mentioned specific embodiments are exemplary, and those skilled in the art can come up with various solutions inspired by the disclosure of the present invention, and these solutions also belong to the disclosure scope of the present invention and fall within the protection scope of the present invention. Those skilled in the art should understand that the present invention specification and its drawings are illustrative and do not constitute a limitation on the claims. The scope of protection of the present invention is defined by the claims and their equivalents. The present invention specification contains multiple inventive concepts, such as "preferably", "according to a preferred embodiment" or "optionally", which means that the corresponding paragraph discloses an independent concept, and the applicant reserves the right to file a divisional application based on each inventive concept.

Claims

1. A patent foramen ovale auxiliary diagnosis device based on Valsalva maneuver, include: An air blowing unit (100) for measuring the air blowing pressure of a patient to be tested (600); An electrocardiogram monitoring unit (200) is used to measure changes in the electrocardiogram of a patient to be tested (600); A contrast agent injection unit (300) is used to inject a contrast agent (310) into a patient to be tested (600); It is characterized in that When the blowing pressure of the patient to be tested (600) fed back by the blowing unit (100) reaches a first predetermined threshold and is maintained for a predetermined time, the control unit (500) starts to request the electrocardiogram change rate of the patient to be tested (600) output by the electrocardiogram monitoring unit (200); When it is determined that the electrocardiogram change rate of the patient to be tested (600) has a change inflection point related to the Valsalva maneuver, the control unit (500) sends a prompt message to the contrast agent injection unit (300) to input the contrast agent (310); In response to received contrast medium intravenous input start information from the contrast medium injection unit (300), the control unit (500) issues an air blowing instruction to the patient to be tested (600) via the prompt unit (510); and when it is determined that the air blowing pressure of the patient to be tested (600) measured by the air blowing unit (100) is lower than a second predetermined threshold, the control unit (500) issues an instruction to record the blood flow dynamics in the heart via the prompt unit (510); The determination of the inflection point of the change of the electrocardiogram change rate associated with the Valsalva maneuver in time is performed as follows: S01: Start initial monitoring of ECG change rate; S02: When the blowing pressure reaches the standard, monitor the sudden change of ECG rate; S03: identifying the inflection point of the change of the electrocardiogram change rate; when the mutation amplitude exceeds the change amplitude from the time point when the air blowing starts to the time point when the air blowing pressure reaches the first predetermined threshold, the time point when the mutation amplitude occurs is determined as the inflection point; the control unit (500) analyzes the electrocardiogram change rate data from the start of the air blowing to the time when the pressure reaches the standard, and finds the mutation amplitude; when it is monitored that the mutation amplitude exceeds the maximum change amplitude during the previous monitoring period, and the degree of excess reaches or exceeds a preset percentage, the time point when the mutation amplitude occurs is determined as the inflection point of the change of the electrocardiogram change rate related to the Valsalva maneuver; S04: Preparation for contrast medium injection; S05: The timing of synchronous contrast agent injection and the inflection point of the ECG change rate; S06: Record cardiac blood flow dynamics.

2. The auxiliary diagnostic device for patent foramen ovale based on Valsalva maneuver according to claim 1, It is characterized in that When a blowing command is issued, the control unit (500) generates labeling prompt information through the prompt unit (510), and the artificial intelligence semantic training model (540) in the control unit (500) labels the electrocardiogram change rate of the patient to be tested (600) sent by the electrocardiogram monitoring unit (200), thereby forming a training set of electrocardiogram change rates.

3. The auxiliary diagnostic device for patent foramen ovale based on Valsalva maneuver according to claim 2, It is characterized in that When the control unit (500) issues a blowing instruction through the prompt unit (510), the blowing unit (100) monitors the blowing pressure of the pipeline (140) and its changes, The control unit (500) triggers a timing instruction for a timer (560) connected thereto to start timing based on the information condition that the blowing pressure reaches a first predetermined threshold; When the time for the insufflation pressure to reach the first predetermined threshold reaches a predetermined duration, the control unit (500) generates instruction information for the patient to be tested (600) to hold his breath and timing prompt information for the breath-holding duration.

4. The patent foramen ovale auxiliary diagnosis device based on Valsalva maneuver according to any one of claims 1 to 3, It is characterized in that In response to the end information of the contrast medium intravenous input of the contrast medium injection unit (300), the control unit (500) issues an exhalation instruction to the patient to be tested (600) through the prompt unit (510).

5. The auxiliary diagnostic device for patent foramen ovale based on Valsalva maneuver according to claim 4, It is characterized in that The blowing unit (100) comprises a pressure sensor (110), a pressure communication port (120), a blowing assembly (130) and a pipeline (140). The pressure sensor (110) is arranged in the pipe (140) connected to the blowing assembly (130) to collect the blowing pressure; The pressure sensor (110) sends data information of the blowing pressure to the control unit (500) via the pressure communication port (120).

6. The patent foramen ovale auxiliary diagnosis device based on Valsalva maneuver according to claim 4, It is characterized in that The electrocardiogram changes measured by the electrocardiogram monitoring unit (200) include changes in heart rate, changes in P waves, and changes in QRS complex waves; The electrocardiogram monitoring unit (200) compares the electrocardiograms of the patient (600) to be tested before and after the Valsalva maneuver to measure the electrocardiogram changes.

7. The auxiliary diagnostic device for patent foramen ovale based on Valsalva maneuver according to claim 4, It is characterized in that The device also includes a display unit (700), Based on the change in the insufflation pressure, the control unit (500) controls the display unit (700) to display the change in the insufflation pressure in different pressure ranges in the form of a sign change, so as to remind the patient to be tested (600) or medical staff of the current insufflation situation.

8. The auxiliary diagnostic device for patent foramen ovale based on Valsalva maneuver according to claim 7, It is characterized in that The control unit (500) synchronously displays the insufflation pressure and its changes, timing information and electrocardiogram changes through the display unit (700).

9. The auxiliary diagnostic device for patent foramen ovale based on Valsalva maneuver according to claim 4, It is characterized in that When the heart rate of the patient to be tested (600) slows down and reaches a preset heart rate threshold, the control unit (500) sends a prompt message to the contrast agent injection unit (300) to input the contrast agent (310).

10. The patent foramen ovale auxiliary diagnosis device based on Valsalva maneuver according to claim 4, It is characterized in that During the preparation of the contrast agent (310), the contrast agent (310) is uniformly mixed with air by repeatedly drawing the syringe (320) to form a uniform mixture of air and the contrast agent (310).

Citation Information

Patent Citations

  • Foaming injector for screening foramen ovale

    CN114272470A

  • Method for evaluating right-to-left shunt to induce intrathoracic negative pressure

    CN111345850A

  • Right heart acoustic radiography Warshi action pressure detector

    CN114366063A

  • Valsalva respiratory pressure detection method and device

    CN114617545A

  • Right side heartfelt wishes radiography auxiliary examination system

    CN206499619U